P
Pedro A Piedra
Researcher at University of the Witwatersrand
Publications - 3
Citations - 532
Pedro A Piedra is an academic researcher from University of the Witwatersrand. The author has contributed to research in topics: Clinical endpoint & Vaccination. The author has an hindex of 3, co-authored 3 publications receiving 318 citations. Previous affiliations of Pedro A Piedra include University of Texas at Austin & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.
Natalie I Mazur,Deborah Higgins,Marta C. Nunes,José A. Melero,Annefleur C Langedijk,Nicole Horsley,Ursula J. Buchholz,Peter J. M. Openshaw,Jason S. McLellan,Janet A. Englund,Asuncion Mejias,Ruth A. Karron,Eric A. F. Simões,Ivana Knezevic,Octavio Ramilo,Pedro A Piedra,Helen Y. Chu,Ann R. Falsey,Harish Nair,Leyla Kragten-Tabatabaie,Anne Greenough,Eugenio Baraldi,Nikolaos G. Papadopoulos,Johan Vekemans,Fernando P. Polack,Mair Powell,Ashish Satav,Edward E. Walsh,Renato T. Stein,Barney S. Graham,Louis Bont +30 more
TL;DR: This Review provides a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.
Journal ArticleDOI
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants
Shabir A. Madhi,Fernando P. Polack,Pedro A Piedra,Flor M. Munoz,Adrian Trenholme,Eric A. F. Simões,Geeta K. Swamy,Sapeckshita Agrawal,Khatija Ahmed,Allison August,Abdullah H Baqui,Anna M. Calvert,Janice Chen,Iksung Cho,Mark F Cotton,Clare L. Cutland,Janet A. Englund,Amy Fix,Bernard Gonik,Laura Hammitt,Paul T. Heath,Joanne De Jesus,Christine E. Jones,Asma Khalil,David W. Kimberlin,Romina Libster,Conrado J Llapur,Marilla Lucero,Gonzalo Pérez Marc,Helen Marshall,Masebole Masenya,Federico Martinón-Torres,Jennifer K. Meece,Terry Nolan,Ayman M. Osman,Kirsten P Perrett,Joyce S Plested,Peter Richmond,Matthew D. Snape,Julie H Shakib,Vivek Shinde,Tanya Stoney,D Nigel Thomas,Alan T.N. Tita,Michael W. Varner,Manu Vatish,Keith Vrbicky,Judy Wen,Khalequ Zaman,Heather J. Zar,Gregory M. Glenn,Louis Fries +51 more
TL;DR: RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success criterion for efficacy against RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of life, and the suggestion of a possible benefit with respect to other end-point events involving RSv-associated respiratory disease in infants warrants further study.
Journal ArticleDOI
Clinical Endpoints for Respiratory Syncytial Virus Prophylaxis Trials in Infants and Children in High-income and Middle-income Countries.
Eric A. F. Simões,Xavier Carbonell-Estrany,Theresa Guilbert,Jonathan M. Mansbach,Pedro A Piedra,Octavio Ramilo,Robert C. Welliver +6 more
TL;DR: A panel of 7 RSV experts was convened to evaluate the challenges of defining RSV prevention endpoints for clinical trials and to develop endpoints that are clinically meaningful while minimizing subjectivity and bias to achieve sufficient consistency of response for regulatory approval.